Prometheus Biosciences Revenue and Competitors

Claim your profile

Location

#4077

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Prometheus Biosciences's estimated annual revenue is currently $2.6M per year.(i)
  • Prometheus Biosciences's estimated revenue per employee is $27,527
  • Prometheus Biosciences's total funding is $451.8M.
  • Prometheus Biosciences's current valuation is $1.4B. (January 2022}

Employee Data

  • Prometheus Biosciences has 93 Employees.(i)
  • Prometheus Biosciences grew their employee count by 37% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$27.4M146-5%$160MN/A
#2
$3.7M24N/AN/AN/A
#3
$18.1M93-3%$24.1MN/A
#4
$47.1M304-3%N/AN/A
#5
$48.1M28014%$403MN/A
#6
$459.2M206854%$242.6MN/A
#7
$0.9M14133%$6.1MN/A
#8
$14.9M79-12%$140MN/A
#9
$29M187-1%N/AN/A
#10
$3.7M24N/AN/AN/A

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

keywords:N/A

$451.8M

Total Funding

93

Number of Employees

$2.6M

Revenue (est)

37%

Employee Growth %

$1.4B

Valuation

N/A

Accelerator

Prometheus Biosciences News

2022-04-20 - Prometheus Biosciences Breaks Below 200-Day Moving Average - Notable for RXDX

In trading on Monday, shares of Prometheus Biosciences Inc (Symbol: RXDX) crossed below their 200 day moving average of $31.68,...

2022-04-06 - Difficult-to-treat inflammatory bowel disease: results from a ...

... Cornerstones Health, and Imedex; and as a consultant or adviser to Boehringer Ingelheim, Gilead Sciences, Prometheus Biosciences, Takeda, UCB Biopharma,...

2022-03-30 - Prometheus Biosciences Initiates Third Phase 2 Study of ...

Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).

2020-12-15 - Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25.1M93N/AN/A
#2
$18.1M93-3%$24.1M
#3
$23.3M930%N/A
#4
$28.6M93N/AN/A
#5
$27M9324%N/A